Interventional Software for Multi-immunotherapy of Solid Tumors

This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by intra-tumor (IT) injection of multiple drugs including CTLA4, PD1, and/or PDL1 antibodies combined with drugs-eluting beads loaded with IL2, chemodrug, anti-angiogenesis drug, et. al that will be recommended by an AI-based medical software named IRSW-MIM developed by a cooperating company.

Trial Details

NCT ID
NCT06478108
Phase
PHASE2 / PHASE3
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • IRSW-MIM
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Cytohistological confirmation is required for diagnosis of cancer.
  • Signed informed consent before recruiting.
  • Age above 18 years with estimated survival over 3 months.
  • Child-Pugh class A or B/Child score \> 7; ECOG score \< 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →